Compare · ABBV vs ANTX
ABBV vs ANTX
Side-by-side comparison of AbbVie Inc. (ABBV) and AN2 Therapeutics Inc. (ANTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and ANTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $500.94B, about 3750.0x ANTX ($133.6M).
- Over the past year, ABBV is up 25.8% and ANTX is up 181.7% - ANTX leads by 155.8 points.
- ABBV has been more active in the news (19 items in the past 4 weeks vs 4 for ANTX).
- ABBV has more recent analyst coverage (25 ratings vs 13 for ANTX).
- Company
- AbbVie Inc.
- AN2 Therapeutics Inc.
- Price
- $285.46+0.75%
- $3.38-5.98%
- Market cap
- $500.94B
- $133.6M
- 1M return
- +8.10%
- -31.16%
- 1Y return
- +25.84%
- +181.67%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2022
- News (4w)
- 19
- 4
- Recent ratings
- 25
- 13
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
AN2 Therapeutics Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Latest ABBV
- SEC Form 8-K filed by AbbVie Inc.
- AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
- New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
- AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
- SEC Form 8-K filed by AbbVie Inc.
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
- AbbVie to Host Third-Quarter 2026 Earnings Conference Call
- FDA Approval for JUVMO issued to ABBVIE INC
Latest ANTX
- SEC Form 4 filed by AN2 Therapeutics Inc.
- SEC Form 4 filed by AN2 Therapeutics Inc.
- SEC Form 4 filed by AN2 Therapeutics Inc.
- AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
- Chief Medical Officer Trenor Cameron C. Iii was granted 116,667 shares (SEC Form 4)
- AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
- SEC Form S-8 filed by AN2 Therapeutics Inc.
- Director Readnour Robin Shane sold $6,675 worth of shares (1,108 units at $6.02) as part of a pre-agreed trading plan (SEC Form 4)
- Director Readnour Robin Shane sold $97,323 worth of shares (16,119 units at $6.04) as part of a pre-agreed trading plan (SEC Form 4)
- Director Fitzpatrick Margaret M bought $11,602 worth of shares (2,098 units at $5.53), increasing direct ownership by 24% to 10,708 units (SEC Form 4)